Loading organizations...
§ Private Profile · Misgav, HaZafon, Israel
Biopharmaceutical company discovers and develops novel immunotherapies for cancer and autoimmune diseases, enabling intracellular delivery.
Biond Biologics is a biopharmaceutical company based in Misgav, Israel, that discovers and develops novel targeted immunotherapies for cancer and autoimmune diseases. The enterprise focuses on overcoming tumor immune evasion and targeting intracellular proteins utilizing its proprietary INspire delivery platform. The clinical-stage firm advances its drug candidates through strategic out-licensing agreements, highlighted by a 2021 global licensing deal with Sanofi for its lead oncology asset that included a $125 million upfront payment. To support its research and development pipeline, the private biotech has secured multiple financing rounds, including a $17 million Series B and a $15 million Series C. These recent equity rounds were backed by institutional and corporate venture investors such as Israel Biotech Fund, Deep Insight, and BMS. Biond Biologics was founded in 2016 by Tehila Ben Moshe, Ori Shilo, and David Sidransky.
Biond Biologics has raised $32.0M across 2 funding rounds.
Biond Biologics has raised $32.0M in total across 2 funding rounds.
Biond Biologics has raised $32.0M in total across 2 funding rounds.
Biond Biologics's investors include Barak Ben-Eliezer, Harel Insurance Investments & Financial Services, Heritage Group, David Sidransky, Celgene, SBI JI Innovation Fund.
Biond Biologics has raised $32.0M across 2 funding rounds. Most recently, it raised $15.0M Series C in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 3, 2021 | $15M Series C | Barak BEN Eliezer | Harel Insurance Investments & Financial Services, Heritage Group | Announced |
| Jan 8, 2019 | $17M Series B | Harel Insurance Investments & Financial Services, David Sidransky | Celgene, SBI JI Innovation Fund | Announced |